#Sweden #Stockholm #SciBase #Rights Issue #Bergs Securities

SciBase Announces Share Issuance for Guarantee Compensation

On October 7, 2026, SciBase Holding AB (publ) made a significant announcement regarding its financial maneuvers tied to a completed rights issue. The company resolved to issue 60,000 new shares to Bergs Securities AB, acting as the guarantor for the rights issue.

The decision is part of the guarantee compensation stipulated in the agreement made on September 3, 2026, following the company's rights issue announcement. Under this agreement, Bergs Securities was entitled to a guarantee compensation amounting to 10 percent of the guaranteed total of approximately SEK 24.2 million.

Breakdown of the Compensation Issue

The shares will be issued at a subscription price of SEK 15 each, equivalent to the price during the rights issue. The payment for these shares will be through a set-off against a claim of SEK 0.9 million that Bergs Securities has for guarantee compensation. The entire allotment of shares in the compensation issue has been subscribed and allotted, marking an important step in fulfilling SciBase's contractual obligations.

This issuance is notable as it deviates from the preferential rights bestowed upon existing shareholders. The SciBase Board of Directors believes that this method of payment in new shares rather than cash is in the best interest of the company and its shareholders. It allows the company to maintain liquidity for its operational needs while still honoring its commitment to the guarantor.

Financial Impacts of the Share Issuance

Post this compensation issue, the number of shares outstanding will rise from 14,059,787 to 14,119,787, leading to an increase in share capital by SEK 300,000. Despite this increase, the dilution effect on existing shareholders is minimal, estimated at around 0.4 percent, which is a factor to consider for investors.

The decision to maintain a subscription price that reflects market conditions results from arm's length negotiations between SciBase and Bergs Securities, ensuring that the terms remain competitive and aligned with market prices.

Background and Future Outlook

SciBase, a leader in medical technology centered around dermatological health, has been operational since 2015 on the Nasdaq First North Growth Market. With over two decades of research backing its initiatives, the company's innovation in dermatology revolves around its unique AI and advanced EIS technology platform, Nevisense. Its focus on early detection and preventative care continues to drive SciBase's vision to enhance diagnostic accuracy and patient outcomes in skin health management.

The company has engaged with several financial advisers for the rights issue, including Bergs Securities and Birchtree Advisory, with legal advice provided by BAHR. These professional partnerships are designed to navigate the intricacies of such financial undertakings, positioning SciBase for continued growth in a competitive market.

In summary, SciBase's strategic decision to issue shares as part of its financial commitments positions the company favorably for future endeavors, enhancing both its capital structure and operational capabilities while allowing for sustained liquidity. Stakeholders will be watching closely how these developments unfold and impact the company's trajectory in the coming months.